Lookup NU author(s): Dr Stuart Rundle,
Dr Yvette Drew,
Professor Nicola Curtin
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of ATR and its major downstream target, CHK1, in the DDR and why cancer cells are particularly reliant on the ATR-CHK1 pathway, providing the rationale for targeting these kinases, and validation of this hypothesis by genetic manipulation. The recent development of specific inhibitors and preclinical data using these inhibitors not only as chemosensitisers and radiosensitisers but also as single agents to exploit specific pathologies of tumour cells is described. These potent and specific inhibitors have now entered clinical trial and early results are presented.
Author(s): Rundle S, Bradbury A, Drew Y, Curtin NJ
Publication type: Review
Publication status: Published
Online publication date: 27/04/2017
Acceptance date: 25/04/2017
ISSN (print): 2072-6694
Publisher: MDPI AG